The Impact of Pharmacist Interventions on Quality Use of Medicines,Quality of Life,and Health Outcomes in People with Dementia and/or Cognitive Impairment: A Systematic Review
Restricted accessResearch articleFirst published online September 3, 2019
The Impact of Pharmacist Interventions on Quality Use of Medicines,Quality of Life,and Health Outcomes in People with Dementia and/or Cognitive Impairment: A Systematic Review
Medication use in people with dementia and/or cognitive impairment (PWD/CI) is challenging. As medication experts, pharmacists have an important role in improving care of this vulnerable population.
Objective:
Systematically review evidence for the effectiveness of pharmacist-led interventions on quality use of medicines, quality of life, and health outcomes of PWD/CI.
Methods:
A systematic review was conducted using MEDLINE, EMBASE, PsycINFO, Allied and Complementary Medicine (AMED) and Cumulative index to Nursing and Allied Health Literature (CINAHL) databases from conception to 20 March 2017. Full articles published in English were included. Data were synthesized using a narrative approach.
Results:
Nine studies were eligible for inclusion. All studies were from high-income countries and assessed pharmacist-led medication management services. There was great variability in the content and focus of services described and outcomes reported. Pharmacists were found to provide a number of cognitive services including medication reconciliation, medication review, and medication adherence services. These services were generally effective with regards to improving quality use of medicines and health outcomes for PWD/CI and their caregivers, and for saving costs to the healthcare system. Pharmacist-led medication and dementia consultation services may also improve caregiver understanding of dementia and the different aspects of pharmacotherapy, thus improving medication adherence.
Conclusion:
Emerging evidence suggests that pharmacist-led medication management services for PWD/CI may improve outcomes. Future research should confirm these findings using more robust study designs and explore additional roles that pharmacists could undertake in the pursuit of supporting PWD/CI.
PrinceM, WimoA, GuerchetM, AliGC, WuYT, PrinaM (2015) World Alzheimer Report 2015: The Global Impact of Dementia. Alzheimer’s Disease International, London.
2.
Australian Institute of Health and Welfare
(2012) Cat. no. AGE 70. AIHW. Canberra.
ReeveE, TrenamanSC, RockwoodK, HilmerSN (2017) Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol13, 651–667.
5.
SomersM, RoseE, SimmondsD, WhitelawC, CalverJ, BeerC (2010) Quality use of medicines in residential aged care. Aust Fam Physician39, 413–416.
6.
BraunerDJ, MuirJC, SachsGA (2000) Treating nondementia illnesses in patients with dementia. JAMA283, 3230–3235.
7.
TaylorJS, DeMersSM, VigEK, BorsonS (2012) The disappearing subject: Exclusion of people with cognitive impairment and dementia from geriatrics research. J Am Geriatr Soc60, 413–419.
8.
Rollin-SillaireA, BreuilhL, SalleronJ, BomboisS, CassagnaudP, DeramecourtV, MackowiakMA, PasquierF (2013) Reasons that prevent the inclusion of Alzheimer’s disease patients in clinical trials. Br J Clin Pharmacol75, 1089–1097.
9.
NgoJ, Holroyd-LeducJM (2015) Systematic review of recent dementia practice guidelines. Age Ageing44, 25–33.
10.
BanerjeeS (2009) The use of antipsychotic medication for people with dementia: Time for action. Department of Health, London, UK.
11.
American Psychiatric Association
(1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), American Psychiatric Association, Washington, DC.
12.
StarrJM, WhalleyLJ (1994) Drug-induced dementia. Incidence, management and prevention. Drug Saf11, 310–317.
13.
BowenJD, LarsonEB (1993) Drug-induced cognitive impairment: Defining the problem and finding solutions. Drugs Aging3, 349–357.
14.
SorbiS, HortJ, ErkinjunttiT, FladbyT, GainottiG, GurvitH, NacmiasB, PasquierF, PopescuBO, RektorovaI, ReligaD, RusinaR, RossorM, SchmidtR, StefanovaE, WarrenJD, ScheltensP, DementiaESP (2012) EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol19, 1159–1179.
15.
CipolleR, StrandL, MorleyP (1998) Pharmaceutical care practice, McGraw-Hill Companies, Inc, New York.
16.
BarnsteinerJH (2008) Chapter 38: Medication reconciliation. In Patient Safety and Quality: An Evidence-Based Handbook for Nurses,
HughesRG, ed. Agency for Healthcare Research and Quality (US), Rockville, MD.
17.
Task Force on Medicines Partnership and The National Collaborative Medicines Management Services Programme, Room for Review: A guide to medication review: The agenda for patients, practitioners and managers, http://www.npc.nhs.uk/review_medicines/intro/resources/room_for_review.pdf, Accessed 15 August, 2011.
18.
StaffordA (2015) The pharmacist’s role in supporting people living with dementia in the community. AUST PHARM36–39.
Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Ottawa Hospital Research Institute, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, Accessed 17 January, 2018.
23.
MoherD, LiberatiA, TetzlaffJ, AltmanDG, GroupP (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med151, 264–269,W264.
24.
NakamuraK, WatanabeN, OhkawaH, AndoM, OguraY, FunabikiS, KumeA, UranoK, OsadaT, YamamuraK (2014) Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer’s disease. Patient Prefer Adherence8, 1223–1228.
25.
NanaumiY, OndaM, TsubotaK, TanakaR, MukaiY, MatobaS, TanakaY, ArakawaY (2015) Effectiveness of Pharmacists’ comprehensive assessment of medication profiles in dementia patients. Yakugaku Zasshi135, 1057–1067.
26.
SakakibaraM, IgarashiA, TakaseY, KameiH, NabeshimaT (2015) Effects of prescription drug reduction on quality of life in community-dwelling patients with dementia. J Pharm Pharm Sci18, 705–712.
ChildA, ClarkeA, FoxC, MaidmentI (2012) A pharmacy led program to review anti-psychotic prescribing for people with dementia. BMC Psychiatry12, 155.
29.
PrenticeA, WrightD (2014) Reducing antipsychotic drugs in care homes. Nurs Times110, 12–15.
30.
PaquinAM, SalowM, RudolphJL (2015) Pharmacist calls to older adults with cognitive difficulties after discharge in a Tertiary Veterans Administration Medical Center: A quality improvement program. J Am Geriatr Soc63, 571–577.
31.
Rojas-FernandezCH, EngM, AllieND (2003) Pharmacologic management by clinical pharmacists of behavioral and psychological symptoms of dementia in nursing home residents: Results from a pilot study. Pharmacotherapy23, 217–221.
32.
EfjestadAS, MoldenE, OksengardAR (2013) Pharmacist-initiated management of antagonistic interactions between anticholinergic drugs and acetyl cholinesterase inhibitors in individuals with dementia. J Am Geriatr Soc61, 1624–1625.
ReisbergB, BorensteinJ, SalobSP, FerrisSH, FranssenE, GeorgotasA (1987) Behavioral symptoms in Alzheimer’s disease: Phenomenology and treatment. J Clin Psychiatry48(Suppl), 9–15.
35.
AriY, KudoK, HosokawaT, WashioM, MiuraH, HisamichiS (1997) Reliability and validity of the Japanese version of the Zarit Caregiver Burden Interview. Psychiatry Clin Neurosci51, 281–287.
36.
KumamotoK, AraiY (2004) Validation of ‘personal strain’ and ‘role strain’: Subscales of the short version of the Japanese version of the Zarit Burden Interview (J-ZBI_8). Psychiatry Clin Neurosci58, 606–610.
37.
RiordanDO, WalshKA, GalvinR, SinnottC, KearneyPM, ByrneS (2016) The effect of pharmacist-led interventions in optimising prescribing in older adults in primary care: A systematic review. SAGE Open Med4, 2050312116652568.
38.
WalshKA, O’RiordanD, KearneyPM, TimmonsS, ByrneS (2016) Improving the appropriateness of prescribing in older patients: A systematic review and meta-analysis of pharmacists’ interventions in secondary care. Age Ageing45, 201–209.
39.
NguyenTA, PhamT, VuHTT, NguyenTX, VuTT, NguyenBTT, NguyenNQ, NguyenBT, NguyenBT, NguyenTN, PhanSV, NguyenAT, PhamTL, DangHT, Kalisch-EllettL, GillamM, PrattN, QiangS, WangH, KanjanarachT, HassaliMAA, BabarZU, RazakAA, ChinwongD, RougheadEE (2018) Use of potentially inappropriate medications in people with dementia in Vietnam and its associated factors. Am J Alzheimers Dis Other Demen33, 423–432.
40.
JohnellK (2015) Inappropriate drug use in people with cognitive impairment and dementia: A systematic review. Curr Clin Pharmacol10, 178–184.
41.
Renom-GuiterasA, ThurmannPA, MirallesR, Klaassen-MielkeR, ThiemU, StephanA, BleijlevensMHC, JolleyD, Leino-KilpiH, HallbergIR, SaksK, Soto-MartinM, ZabaleguiA, MeyerG, ConsortiumR (2018) Potentially inappropriate medication among people with dementia in eight European countries. Age Ageing47, 68–74.
42.
ParsonsC, JohnstonS, MathieE, BaronN, MachenI, AmadorS, GoodmanC (2012) Potentially inappropriate prescribing in older people with dementia in care homes: A retrospective analysis. Drugs Aging29, 143–155.
43.
BosboomPR, AlfonsoH, AlmeidaOP, BeerC (2012) Use of potentially harmful medications and health-related quality of life among people with dementia living in residential aged care facilities. Dement Geriatr Cogn Dis Extra2, 361–371.
44.
CrossAJ, GeorgeJ, WoodwardMC, AmesD, BrodatyH, IlomakiJ, ElliottRA (2016) Potentially inappropriate medications and anticholinergic burden in older people attending memory clinics in Australia. Drugs Aging33, 37–44.
45.
MontastrucF, GardetteV, CantetC, PiauA, Lapeyre-MestreM, VellasB, MontastrucJL, AndrieuS, GroupRF (2013) Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: Be aware of atropinic and benzodiazepine drugs!. Eur J Clin Pharmacol69, 1589–1597.
46.
LauDT, MercaldoND, HarrisAT, TrittschuhE, ShegaJ, WeintraubS (2010) Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer Dis Assoc Disord24, 56–63.
47.
BarryHE, CooperJA, RyanC, PassmoreAP, RobinsonAL, MolloyGJ, DarcyCM, BuchananH, HughesCM (2016) Potentially inappropriate prescribing among people with dementia in primary care: A retrospective cross-sectional study using the enhanced prescribing database. J Alzheimers Dis52, 1503–1513.
48.
GadzhanovaS, RougheadE, RobinsonM (2015) Use of medicines with anticholinergic and sedative effect before and after initiation of anti-dementia medications. Drugs Real World Outcomes2, 53–60.
49.
CarnahanRM, LundBC, PerryPJ, ChrischillesEA (2004) The concurrent use of anticholinergics and cholinesterase inhibitors: Rare event or common practice?J Am Geriatr Soc52, 2082–2087.
50.
RoeCM, AndersonMJ, SpivackB (2002) Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc50, 836–842.
51.
BoudreauDM, YuO, GraySL, RaebelMA, JohnsonJ, LarsonEB (2011) Concomitant use of cholinesterase inhibitors and anticholinergics: Prevalence and outcomes. J Am Geriatr Soc59, 2069–2076.
52.
Australian Government Department of Health and Ageing (2002) The National Strategy for Quality Use of Medicines, Commonwealth of Australia, Canberra, Australia.
53.
FissT, ThyrianJR, WuchererD, AssmannG, KilimannI, TeipelSJ, HoffmannW (2013) Medication management for people with dementia in primary care: Description of implementation in the DelpHi study. BMC Geriatr13, 121.
NguyenTA, RougheadEE (2018) Strength and weaknesses of pharmaceutical policy in relation to rational and responsible medicines use. In Social and Administrative Aspects of Pharmacy in Developing Countries: Present Challenges and Future Solutions, Mohamed IbrahimMIBabarZ, WertheimerAI, eds. Elsevier Inc, The Netherlands.
56.
O’ConnorDW, GriffithJ, McSweeneyK (2010) Changes to psychotropic medications in the six months after admission to nursing homes in Melbourne, Australia. Int Psychogeriatr22, 1149–1153.
57.
PeisahC, SkladzienE (2014) The Use of Restraints and Psychotropic Medications in People with Dementia. A report for Alzheimer’s Australia.
58.
DeclercqT, PetrovicM, AzermaiM, Vander SticheleR, De SutterAIM, van DrielML, ChristiaensT (2013) Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev, CD007726.
59.
PanYJ, WuCS, GauSS, ChanHY, BanerjeeS (2014) Antipsychotic discontinuation in patients with dementia: A systematic review and meta-analysis of published randomized controlled studies. Dement Geriatr Cogn Disord37, 125–140.
60.
HudaniZK, Rojas-FernandezCH (2016) A scoping review on medication adherence in older patients with cognitive impairment or dementia. Res Social Adm Pharm12, 815–829.
61.
El-SaifiN, MoyleW, JonesC, TuffahaH (2018) Medication adherence in older patients with dementia: A systematic literature review. J Pharm Pract31, 322–334.
62.
CampbellNL, BoustaniMA, SkopeljaEN, GaoS, UnverzagtFW, MurrayMD (2012) Medication adherence in older adults with cognitive impairment: A systematic evidence-based review. Am J Geriatr Pharmacother10, 165–177.
63.
MaxwellCJ, StockK, SeitzD, HerrmannN (2014) Persistence and adherence with dementia pharmacotherapy: Relevance of patient, provider, and system factors. Can J Psychiatry59, 624–631.
64.
(2008) Pharmacists can play a bigger role in dementia care. Pharm J281, 354.
65.
BarryHE, ParsonsC, PassmoreAP, HughesCM (2013) Community pharmacists and people with dementia: A cross-sectional survey exploring experiences, attitudes, and knowledge of pain and its management. Int J Geriatr Psychiatry28, 1077–1085.
66.
PrinceM, Comas-HerreraA, KnappM, GuerchetM, KaragiannidouM (2016) World Alzheimer Report 2016. Improving healthcare for people living with dementia: Coverage, quality and costs now and in the future. Alzheimer’s Disease International, London.
